Prospective evaluation of trisomy 21 screening during the second trimester in women over 38 years of age using a serum marker and ultrasonography in 5,163 patients;Evaluation de l'association marqueur serique et echographie du deuxieme trimestre pour le depistage de la trisomie 21 chez les femmes de moins de 38 ans: Etude prospective chez 5 163 patientes

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 27, Issue 6, 1998, Pages 599-604

  Lefebvre, G ^a   Vauthier Brouzes, D ^a   Choukroun, J B ^a   Sebagh, E ^a   Bernard, M ^a   Brochet, C ^a   Lesourd, S ^a   Darbois, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HCG; Trisomy 21; Ultrasonography

Indexed keywords

CHORIONIC GONADOTROPIN;

ADULT; AMNIOCENTESIS; ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; FETUS ECHOGRAPHY; GENETIC SCREENING; GONADOTROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21;

ADULT; AMNIOCENTESIS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; FEMALE; HUMANS; MATERNAL AGE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY, HIGH-RISK; PROSPECTIVE STUDIES; RISK FACTORS; ULTRASONOGRAPHY, PRENATAL;

EID: 0031732631     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rugg JA, Rigi CT, Leung K, Lamar SL, Weish M, Leblanc M, et al. Radial partition immunoassay applied to automated quantification of human choriogonadotrophin with use of two monoclonal antibodies. Clin Chem 1988; 32:1844-8.
2. Giegel JL, Brotherton MM, Cronin P, D'Aquino M, Evans S, Heller ZH, et al. Radial partition immunoassay. Clin Chem 1982;28:1894-8.
3. Ayme S, Aurran Y, Chabal F, Gombert A, Loundou H, Montfort C, et al. Evaluation du risque de trisomie 21 par dosage sérique de l'hormone gonadotrophique chorionique et de l'alpha-fœtoprotéine: résultats de l'enquête pilote nationale. Contracept Fertil Sex 1993;21:133-43.
4. Muller F, Bussières L, Chevallier B. Marqueurs sériques maternels de la trisomie 21 fœtale. Presse Méd 1995;24:1265-9.
5. Poloce F, Roubille M, Gelineau MC. Intérêt des marqueurs sériques biochimiques dans l'évaluation du risque fœtal de trisomie 21. Rev Fr Gynecol Obstet 1997;92:174-81.
6. Vauthier-Brouzes D, Lefebvre G, Sebagh E, Choukroun JB, Bernard M, Lesourd S, et al. Réduction du nombre des amniocentèses pour dépistage de la trisomie 21 chez les femmes de moins de 38 ans par l'association hCG plasmatique et échographie orientée. J Gynecol Obstet Biol Reprod 1995;24:454-5.
7. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down syndrome in early pregnancy. BMJ 1988;297:883-7.
8. Cuckle H. Improved parameters for risk estimation in Down syndrome screening. Prenat Diagn 1995;15:1057-65.
9. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
10. Kellner LH, Weiner Z, Weiss RR, Neuer M, Martin GM, Mueenuddin M, et al. Triple marker (alpha-fœtoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fœtoprotein plus free-b subunit in second trimester maternal serum screening for fetal Down syndrome: a prospective comparison. Am J Obstet Gynecol 1995;173;1306-9.
11. Spencer K, Macri JN, Aitken DA, Connor JM. Free B-hCG as first-trimester marker for fetal trisomy. Lancet 1992;13:1480.
12. Macri JN, Spencer K, Aitken DA, Garver K, Buchanan PD, Muller F, et al. First-trimester free β hCG screening for Down syndrome. Prenat Diagn 1993;13:557-62.
13. Wald NJ, Kennard A, Hackshaw AK. First trimester serum screening for Down syndrome. Prenat Diagn 1995;75: 1127-40.
14. Hurley PA, Ward RHT, Teisner B, Maguiness S, Shrimanker K, Lanzani A, et al. Serum PAPP-A measurements in first-trimester screening for Down syndrome. Prenat Diagn 1993;13;903-8.
15. Brambati B, Macintosh MC, Teisner B, Maguiness S, Shrimanker K, Lanzani A, et al. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993;100:324-6.
16. Scott F, Boogert A, Sinosich M, Anderson J. Establishment and application of a normal range for nuchal translucency across the first trimester. Prenat Diagn 1996;16:629-34.
17. Achiron R, Yagel S, Weissman A, Lipitz S, Mashiach S, Goldman B. Fetal lateral neck cysts: early second trimester transvaginal diagnosis, natural history and clinical significance. Ultrasound Obstet Gynecol 1995;6:396-9.
18. Suchet IB. Ultrasonography of the fetal neck in the first and second trimesters. Part 2. Anomalies of the posterior nuchal region. Can Assoc Radiol J 1995;46:344-52.
19. Nicolaides KH, Brizot ML, Snijdzes RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994;101:782-6.
20. Benacerraf BR. The second-trimester fetus with Down syndrome: detection using sonographic features. Ultrasound Obstet Gynecol 1996;7:147-55.
21. Nyberg DA, Luthy DA, Cheng EY, Sheley RC, Resta RG, Williams MA. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers. Am J Obstet Gynecol 1995;173: 1030-5.
22. Nicolaides KH, Snijders RJM, Gosden CM, Berry C, Campbell S. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992;340:704-7.
23. Hecher K, Snijders R, Nicolaides K. Screening for fetal chromosomal abnormalities by maternal serum biochemistry and ultrasound examination of fetal morphology. Curr Opin Obstet Gynecol 1993;5:170-8.
24. Borell A, Costa D, Martinez JM, Delgado RD, Casals E, Ojuel J, et al. Early midtrimester fetal nuchal thickness: effectiveness as a marker of Down syndrome. Am J Obstet Gynecol 1996;175:45-9.
25. Brumfield CG, Lin S, Conner W, Cosper P, Davis RO, Owen J. Pregnancy outcome following genetic amniocentesis at 11-14 versus 16-19 weeks' gestation. Obstet Gynecol 1996;88:114-8.
26. Salvesen DR, Goble O. Early amniocentesis and fetal nuchal translucency in women requesting karyotyping for advanced maternal age. Prenat Diagn 1995;15:971-4.
27. Nicolaides KH, Brizot ML, Patel F, Snijders R. Comparison of chorion villus sampling and early amniocentesis for karyotyping in 1,492 singleton pregnancies. Fetal Diagn Ther 1996;11:9-15.
28. Johnson JM, Wilson RD, Winsor EJ, Singer J, Dansereau J, Kalousek DK. The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. Fetal Diagn Ther 1996;11:85-93.
29. Borell A, Costa D, Delgado RD, Martinez JM, Borell C, Fortuny A. Interobserver variability of midtrimester fetal nuchal thickness. Eur J Obstet Gynecol Reprod Biol 1997; 72:27-9.
30. Grandjean H, Sarramon MF. Sonographic measurement of nuchal skinfold thirckness for detection of Down syndrome in the second trimester fetus: a multicenter prospective study. The AFDPHE study group. Association française pour le dépistage et la prévention des Handicaps de l'enfant. Obstet Gynecol 1995;85:103-6.
31. De Vore GR, Alfi O. The use of color doppler ultrasound to identify fetuses at increased risk for trisomy 21: alternative for high-risk patients who decline genetic amniocentesis. Obstet Gynecol 1995;85:378-86.
32. Vintzileos AM, Campbell WA, Rodis JF, Gusman ER, Smulian JC, Knuppel RA. The use of second trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet Gynecol 1996; 87:948-52.
33. Vintzileos AM, Campbell WA, Guzman ER, Smulian JC, McLean DA, Ananth CV. Second trimester ultrasound markers for detection of trisomy 21: which markers are best? Obstet Gynecol 1997;89:941-4.
34. Vintzileos AM, Egan JFX, Smulian JC, Campbell WA, Guzman ER, Rodis JF. Adjusting the risk for trisomy 21 by a simple ultrasound method using fetal long-bone biometry. obstet Gynecol 1996;S7:953-8.
35. Vintzileos AM, Egan JFX. Adjusting the risk for fetal trisomy 21 on the basis of second trimester ultrasonography. Am J Obstet Gynecol 1995;172:837-44.